Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti infectives. Galapagos approach is to develop drugs that stop or reverse a disease state using novel targets that are identified through a patent protected target discovery platform. Galapagos also provides access to its target and drug discovery platform through its services division, BioFocus and Argenta, which offers a full suite of target to drug discovery products and services to pharmaceutical and biotech companies.
Quote | Galapagos NV (NASDAQ:GLPG)
Last: | $24.89 |
---|---|
Change Percent: | 0.0% |
Open: | $25.39 |
Close: | $24.89 |
High: | $25.475 |
Low: | $24.86 |
Volume: | 65,908 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Galapagos NV (NASDAQ:GLPG)
2024-06-25 05:53:06 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galapagos (NASDAQ: GLPG ) just reported results for the first quarter of 2024. Galapagos reported earnings per share of $1.52. This was above the analyst estimate for EPS ...
2024-05-30 17:02:10 ET More on Adaptimmune Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript Adaptimmune: Huge Opportunity Amid Their Setback With Genentech Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Adaptimmune GA...
Message Board Posts | Galapagos NV (NASDAQ:GLPG)
Subject | By | Source | When |
---|---|---|---|
Galapagos announces full year 2022 results and outlook | abrooklyn | investorshub | 03/31/2023 3:48:40 PM |
whytestocks: $GLPG News Article - Correction: Jyseleca (filgotinib) approved in Japan for rheumatoid | whytestocks | investorshangout | 09/25/2020 5:50:47 PM |
$GLPG and $GILD both are hot! | BottomBounce | investorshub | 06/08/2020 5:45:46 PM |
I think an upcoming merger is far more important... https://www.bloomberg.com/n | qi | investorshub | 06/07/2020 2:44:49 PM |
Galapagos $GLPG & $GILD Shares Rise On | BottomBounce | investorshub | 06/05/2020 5:09:37 PM |
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...
2024-05-11 10:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...